Skip to main content

Advertisement

SpringerLink
Log in

Identification of novel serum biomarkers in child nephroblastoma using proteomics technology

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

To screen and identify serum biomarkers for nephroblastoma in children using surface-enhanced laser desorption/ionization (SELDI) and other proteomics technologies. The surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI–TOF-MS) was used to identify biomarkers in 100 children with nephroblastoma and 30 gender and age-matched normal healthy children. There were 30 cases of pre-operative patients and 70 cases of post-operative patients. Differentially expressed serum proteins were screened. The target proteins were then separated, purified, and analyzed by multidimensional high performance liquid chromatography (HPLC). The peptide mass fingerprints (PMFs) of each protein were obtained after scanning with LC-MS/MS (LTQ). The proteins were identified using SEQUEST and the biological functions and characterizations of these proteins were analyzed with bioinformatic methods. Two differential proteins (m/z 6455.5, 9190.8) were obtained. According to SEQUEST, the molecular masses of this two proteins indicated that they were apolipoprotein C-I and haptoglobin, respectively. Expressions of the two proteins were lower in the pre-surgery group compared with the post-surgery and control group (P < 0.01). In contrast, the expression of this two proteins were higher in the early stage than in the advanced stage of nephroblastoma. Apolipoprotein C-I and haptoglobin may be used as potential biomarkers to predict the degree of malignancy, therapeutic outcomes, and prognosis of nephroblastoma in children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Abbreviations

SELDI–TOF-MS:

Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry

MALDI–TOF-MS:

Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry

HPLC:

High performance liquid chromatography

PMFs:

Peptide mass fingerprints

m/z:

Mass-to-charge ratio

ApoC-I:

Apolipoprotein C-I

Hp:

Haptoglobin

SPA:

Sinapinic acid

SVM:

Support vector machine

CHCA:

α-Cyanoacrylate-4-hydroxy-cinnamic acid

IAM:

Iodine acetamide

References

  1. Hargrave DR et al (2001) Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI). Br J Haematol 112(2):293–299

    Article  CAS  PubMed  Google Scholar 

  2. Eden OB et al (2000) Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980–1997. Medical Research Council Childhood Leukaemia Working Party. Leukemia 14(12):2307–2320

    Article  CAS  PubMed  Google Scholar 

  3. McGregor LM et al (2007) Pediatric cancers in the new millennium: dramatic progress, new challenges. Oncology (Williston Park) 21(7): 809–820; discussion 820, 823–824

    Google Scholar 

  4. Rubnitz JE et al (2004) Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer 101(7):1677–1684

    Article  PubMed  Google Scholar 

  5. Lawn JE, Cousens S, Zupan J (2005) 4 million neonatal deaths: when? Where? Why? Lancet 365(9462):891–900

    Article  PubMed  Google Scholar 

  6. Miniati D et al (2008) Imaging accuracy and incidence of Wilms’ and non-Wilms’ renal tumors in children. J Pediatr Surg 43(7):1301–1307

    Article  PubMed  Google Scholar 

  7. Lindor NM et al (2008) Concise handbook of familial cancer susceptibility syndromes—second edition. J Natl Cancer Inst Monogr 38:1–93

    PubMed  Google Scholar 

  8. Ehrlich PF (2007) Wilms tumor: progress and considerations for the surgeon. Surg Oncol 16(3):157–171

    Article  CAS  PubMed  Google Scholar 

  9. Medeiros LR et al (2009) Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol 142(2):99–105

    CAS  PubMed  Google Scholar 

  10. Tsui KH et al (1997) Diagnosis of prostate cancer: comparison of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. Changgeng Yi Xue Za Zhi 20(1):23–28

    CAS  PubMed  Google Scholar 

  11. Velaiutham S et al (2008) Does the pre-operative value of serum CA15-3 correlate with survival in breast cancer? Asian Pac J Cancer Prev 9(3):445–448

    CAS  PubMed  Google Scholar 

  12. Zhong L, Taylor DL, Whittington RJ (2010) Proteomic profiling of ovine serum by SELDI-TOF MS: optimisation, reproducibility and feasibility of biomarker discovery using routinely collected samples. Comp Immunol Microbiol Infect Dis 33(1):47–63

    Article  PubMed  Google Scholar 

  13. Wang J et al (2008) Proteomic studies of early-stage and advanced ovarian cancer patients. Gynecol Oncol 111(1):111–119

    Article  CAS  PubMed  Google Scholar 

  14. Hong M et al (2009) The potential biomarkers for thromboembolism detected by SELDI-TOF-MS. Thromb Res 123(3):556–564

    Article  CAS  PubMed  Google Scholar 

  15. Huang HL et al (2006) Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 27(8):1641–1650

    Article  CAS  PubMed  Google Scholar 

  16. Song G, Ouyang G, Bao S (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9(1):59–71

    Article  CAS  PubMed  Google Scholar 

  17. Turner GA (1995) Haptoglobin. A potential reporter molecule for glycosylation changes in disease. Adv Exp Med Biol 376:231–238

    CAS  PubMed  Google Scholar 

  18. Marinkovic S, Baumann H (1990) Structure, hormonal regulation, and identification of the interleukin-6- and dexamethasone-responsive element of the rat haptoglobin gene. Mol Cell Biol 10(4):1573–1583

    CAS  PubMed  Google Scholar 

  19. Langlois MR, Delanghe JR (1996) Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42(10):1589–1600

    CAS  PubMed  Google Scholar 

  20. Wassell J (2000) Haptoglobin: function and polymorphism. Clin Lab 46(11–12):547–552

    CAS  PubMed  Google Scholar 

  21. Van Vlierberghe H, Langlois M, Delanghe J (2004) Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin Chim Acta 345(1–2):35–42

    Article  PubMed  Google Scholar 

  22. Melamed-Frank M et al (2001) Structure-function analysis of the antioxidant properties of haptoglobin. Blood 98(13):3693–3698

    Article  CAS  PubMed  Google Scholar 

  23. He Q, Zhang SQ, Chu YL et al (2009) The correlations between HPV16 infection and expressions of c-erbB-2 and bcl-2 in breast carcinoma. Mol Biol Rep 36(4):807–812

    Article  CAS  PubMed  Google Scholar 

  24. Nakano M et al (2008) Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer 122(10):2301–2309

    Article  CAS  PubMed  Google Scholar 

  25. Hoagland LF 4th et al (2007) Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer 110(10):2260–2268

    Article  CAS  PubMed  Google Scholar 

  26. Liu H, Zhang T, Wu B, Huang J, Zhou Y et al (2009) Chronic exposure to exogenous matrilysin induces chemoresistance and enhances Bcl-2 expression in A549 lung adenocarcinoma cells. Mol Biol Rep 36(8):2099–2109

    Article  CAS  PubMed  Google Scholar 

  27. Fujimura T et al (2008) Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int J Cancer 122(1):39–49

    Article  CAS  PubMed  Google Scholar 

  28. Zhao C et al (2007) Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia 9(1):1–7

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This study was supported by National Natural Science Foundation of China (No. 30571930).

Author information

Authors and Affiliations

  1. Department of Pediatric Surgery, First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan Province, China

    Qian Zhang, Jiaxiang Wang, Rui Dong & Shaobo Yang

  2. Cancer Institute of Zhejiang University, Zhengzhou, China

    Shu Zheng

Authors
  1. Qian Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiaxiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rui Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shaobo Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shu Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jiaxiang Wang.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 36 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, Q., Wang, J., Dong, R. et al. Identification of novel serum biomarkers in child nephroblastoma using proteomics technology. Mol Biol Rep 38, 631–638 (2011). https://doi.org/10.1007/s11033-010-0149-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-010-0149-4

Keywords

Search

Navigation